Introduction
Psoriasis is a chronic, recurrent inflammatory skin disease which affects around 2% of the population and is characterized by erythematous and scaly macules and papules of greatly varying degree of involvement. Ciclosporin (Cs) is a therapeutic agent rarely used in the treatment of erythrodermic psoriasis as a monotherapy [1] .
Case Report
We present a 42-year-old male affected with biopsy-proven vulgar psoriasis admitted to our Department for the appearance of an erythrodermic psoriasis (Fig. 1A) . Before admission to the hospital patient suffered from relapsing episodes of diffuse psoriasis, since the age of 19, which responded well to topical emollients and UVB therapy. 5 years ago has suffered from hepatitis C. The laboratory tests did not revealed any abnormalities related to renal and hepatic function. The patient was treated with ciclosporin 2.5 mg/kg per day, doxycycline (2 x 100mg per day) and hydroxyzine tablets for symptomatic relief. The clinical response was not immediate, although at the begining of the third week of the therapy a marked reduction of erythema and scaling was evident. Since week 4 of the treatment, ciclosporin was gradually reduced (0.5 mg/kg per day). Presently patient receives 1.17 mg/kg per day and is under a complete remission (Fig. 1B) . 
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Discussion
Because of hepatitis C in the past, we have consciously disqualified treatment with methotrexate, acitretin or with combined therapy, although combined therapy is often used in psoriasis to increase clinical efficacy and to reduce side effects [2] . This case is noteworthy because we have observed clinical improvement at low doses of Cs alone. The degree of improvement in PASI scores was 85.3 % achieved comparatively late, which obtain with relatively low dose of Cs [3] . This case is negatory to papers reporting, that starting with dosages lower than 3.0 mg/kg daily may lead to insuficient efficacy [4] and strengthens reports suggesting minimising potentially harmful side-effects by treatment with initial daily oral dose of 2.5 -5.0 mg/kg daily, which may be modulated only in a case of insufficient efficacy [5] [6] [7] .
